A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma

被引：0

作者：

A. F. Cardona

L. Rojas

B. Wills

A. Ruiz-Patiño

L. Abril

F. Hakim

E. Jiménez

N. Useche

S. Bermúdez

J. A. Mejía

J. F. Ramón

H. Carranza

C. Vargas

J. Otero

P. Archila

J. Rodríguez

J. Behaine

D. González

J. Jacobo

H. Cifuentes

O. Feo

P. Penagos

D. Pineda

L. Ricaurte

L. E. Pino

C. Vargas

J. C. Marquez

M. I. Mantilla

L. D. Ortiz

C. Balaña

R. Rosell

Z. L. Zatarain-Barrón

O. Arrieta

机构：

[1] Clínica del Country,Clinical and Translational Oncology Group, Institute of Oncology

[2] Foundation for Clinical and Applied Cancer Research (FICMAC),Institute of Neuroscience

[3] Universidad El Bosque,Clinical Oncology Department, Centro Javeriano de Oncología

[4] Hospital Universitario San Ignacio,Faculty of Medicine

[5] Pontificia Universidad Javeriana,Internal Medicine Department

[6] Johns Hopkins University,Neurosurgery Department

[7] Fundación Santa Fe de Bogotá,Division of Neuro

[8] Fundación Santa Fe de Bogotá,radiology, Radiology Department

[9] Clínica del Country,Neurosurgery Department

[10] National Cancer Institute (INC),Neurosurgery Department

[11] Clínica del Country,Division of Neuro

[12] Fundación Santa fe de Bogotá,radiology, Radiology Department

[13] Clínica de Las Américas,Clinical Oncology Department

[14] Hospital Germans Trias i Pujol,Division of Neuro

[15] Instituto Nacional de Cancerología,Oncology, Clinical Oncology Department

来源：

Clinical and Translational Oncology | 2019年 / 21卷

关键词：

Glioblastoma; Second-line therapy; Bevacizumab; Molecular expression classification;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1364 / 1373

页数：9

共 50 条

[21] ANGIOTENSINOGEN GENE SILENCING PREDICTS BEVACIZUMAB RESPONSE IN RECURRENT GLIOBLASTOMA PATIENTS
Urup, Thomas
Gillberg, Linn
Michaelsen, Signe
Christensen, Ib
Broholm, Helle
Lassen, Ulrik
Groenbaek, Kirsten
Poulsen, Hans
[J]. NEURO-ONCOLOGY, 2018, 20 : 162 - 163
[22] Eosinophil and lymphocyte counts predict bevacizumab response and survival in recurrent glioblastoma
Vaios, Eugene J.
Winter, Sebastian F.
Muzikansky, Alona
Nahed, Brian V.
Dietrich, Jorg
[J]. NEURO-ONCOLOGY ADVANCES, 2020, 2 (01)
[23] EGFR Gene Amplification Predicts a Poor Response to Bevacizumab in Recurrent Glioblastoma
Hovinga, Koos E.
McCrea, Heather J.
Zheng, Junting
Tabar, Viviane
[J]. NEUROSURGERY, 2017, 64 : 265 - 265
[24] Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma
Choi, Seung Won
Shin, Hyemi
Sa, Jason K.
Cho, Hee Jin
Koo, Harim
Kong, Doo-Sik
Seol, Ho Jun
Nam, Do-Hyun
[J]. CANCER MEDICINE, 2018, 7 (05): : 1774 - 1783
[25] Diffusion restriction as a predictor of response in recurrent glioblastoma patients receiving bevacizumab
Wu, J.
Gilbert, M. R.
De Groot, J. F.
Yung, W. A.
Puduvalli, V. K.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[26] ANGIOTENSINOGEN PROMOTER METHYLATION TO PREDICT BEVACIZUMAB RESPONSE IN RECURRENT GLIOBLASTOMA PATIENTS
Urup, Thomas
Gillberg, Linn
Kaastrup, Katja
Lu, Maja Schuang
Michaelsen, Signe Regner
Larsen, Vibeke A.
Christensen, Ib Jarle
Broholm, Helle
Lassen, Ulrik
Gronbaek, Kirsten
Poulsen, Hans Skovgaard
[J]. NEURO-ONCOLOGY, 2019, 21 : 149 - 149
[27] Clinical outcomes in recurrent glioblastoma with bevacizumab therapy: An analysis of the literature
Tipping, Matthew
Eickhoff, Jens
Robins, H. Ian
[J]. JOURNAL OF CLINICAL NEUROSCIENCE, 2017, 44 : 101 - 106
[28] Bevacizumab for recurrent glioblastoma: a systematic review and meta-analysis
Zhang, T.
Xin, Q.
Kang, J-M
[J]. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (21) : 6480 - 6491
[29] Bevacizumab in recurrent glioblastoma: open issues
Franceschi, Enrico
Bartolotti, Marco
Brandes, Alba A.
[J]. FUTURE ONCOLOGY, 2015, 11 (19) : 2655 - 2665
[30] OUTCOME OF CONTINUATION OF BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA
Chamberlain, Marc C.
[J]. NEURO-ONCOLOGY, 2011, 13 : 41 - 42

← 1 2 3 4 5 →